Understanding how impaired VLDL secretion affects liver disease progression
Impaired VLDL secretion in progression of NAFLD and NASH in mice and humans
['FUNDING_R01'] · WASHINGTON UNIVERSITY · NIH-10881216
This study is looking at how problems with a type of fat in the blood can lead to liver diseases like NAFLD and NASH, and it aims to find out if certain genes make some people more likely to get these conditions, so we can develop better treatments and help those at risk.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | WASHINGTON UNIVERSITY (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10881216 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms behind impaired Very Low-Density Lipoprotein (VLDL) secretion and its role in the progression of liver diseases such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). By studying both mice and human patients, the research aims to identify specific genetic factors that contribute to liver damage and cancer development. The approach includes using genetically modified mouse models to explore shared pathways that could lead to new treatment strategies for reversing liver fibrosis and preventing cancer. Patients may be involved in identifying those at risk for disease progression based on their genetic profiles.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with NAFLD or NASH, particularly those with genetic factors affecting VLDL secretion.
Not a fit: Patients with liver diseases unrelated to VLDL secretion impairment or those without NAFLD or NASH may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment strategies that prevent the progression of liver disease and reduce the risk of liver cancer.
How similar studies have performed: Other research has shown promise in understanding the genetic factors influencing liver disease progression, suggesting that this approach could yield valuable insights.
Where this research is happening
SAINT LOUIS, UNITED STATES
- WASHINGTON UNIVERSITY — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: DAVIDSON, NICHOLAS O. — WASHINGTON UNIVERSITY
- Study coordinator: DAVIDSON, NICHOLAS O.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.